금연 및 니코틴 중독 치료 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Smoking Cessation And Nicotine De-Addiction Market reached USD 25.5 billion in 2024 and is projected to grow at a CAGR of 12% between 2025 and 2034. The increasing awareness of the severe health risks associated with smoking, including lung cancer, cardiovascular diseases, and respiratory disorders, is fueling the demand for nicotine de-addiction products. Government initiatives promoting anti-smoking campaigns, stricter regulations on tobacco products, and rising consumer preference for healthier alternatives are further accelerating market expansion.

With a growing emphasis on smoking cessation programs, nicotine replacement therapies (NRT), and advanced drug formulations, the market is poised for substantial growth over the coming decade. Additionally, pharmaceutical advancements and the introduction of next-generation nicotine replacement solutions, such as prescription medications and behavioral support therapies, are making it easier for individuals to quit smoking successfully. The rising adoption of digital health platforms and mobile applications offering smoking cessation support is further contributing to the growing awareness and accessibility of these solutions.

The market is categorized by product type, including nicotine replacement therapy (NRT), drug therapy, and E-cigarettes and vapes. In 2024, the E-cigarettes and vapes segment dominated the market, accounting for 50% of the total share. The rising preference for these alternatives stems from their perceived reduced harm compared to conventional cigarettes. Young adults, particularly in North America and Europe, are leading the shift toward vaping devices, attracted by their convenience, variety of flavors, and technological advancements. Increasing regulatory approvals for controlled nicotine delivery through vaping products and growing investments by key players in innovative, harm-reduction technologies are further driving segment growth.

When examining the market by the route of administration, it is segmented into oral, transdermal, nasal, inhalation, and sublingual methods. In 2024, the inhalation segment led the market, holding a 50% share. The segment's dominance is largely attributed to the rising adoption of nicotine inhalers, vapes, and E-cigarettes. With continuous advancements in inhalation-based therapies, manufacturers are introducing novel nicotine inhalers designed to deliver controlled doses of nicotine, enhancing their effectiveness as a smoking cessation aid. Consumer preference for inhalation methods is driven by their ability to replicate the experience of traditional smoking while minimizing exposure to harmful chemicals.

The U.S. Smoking Cessation and Nicotine De-Addiction Market was valued at USD 8.9 billion in 2024 and is projected to reach USD 26.7 billion by 2034. The increasing prevalence of lung cancer and other smoking-related diseases in the U.S. is driving the demand for smoking cessation products. A growing number of smokers, particularly young adults, are actively seeking alternatives to traditional cigarettes, leading to a surge in demand for NRT, prescription medications, and behavioral therapies. The widespread adoption of E-cigarettes and vapes as a transitional aid for quitting smoking is further supporting market growth. Expanding research and development efforts, alongside government-backed anti-smoking initiatives, are expected to create significant opportunities for market players in the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing awareness of health risks associated with smoking
    • 3.2.1.2 Government regulations and anti-smoking campaigns
    • 3.2.1.3 Advancements in smoking cessation products
    • 3.2.1.4 Rise in smoking-related diseases and healthcare costs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of smoking cessation products
    • 3.2.2.2 Psychological and physical addiction challenges
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Nicotine replacement therapy
  • 5.2.1 Nicotine gum
  • 5.2.2 Nicotine patches
  • 5.2.3 Nicotine lozenges
  • 5.2.4 Nicotine nasal sprays
  • 5.2.5 Nicotine inhalers
• 5.3 Drug therapy
  • 5.3.1 Varenicline (Chantix)
  • 5.3.2 Bupropion (Zyban)
• 5.4 E-cigarettes and vapes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Transdermal
• 6.4 Nasal
• 6.5 Inhalation
• 6.6 Sublingual

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alkalon
• 9.2 British American Tobacco
• 9.3 Cipla
• 9.4 Dr. Reddy’s Laboratories
• 9.5 GlaxoSmithKline
• 9.6 Imperial Brands
• 9.7 Johnson & Johnson
• 9.8 Lupin
• 9.9 NJOY
• 9.10 Novartis
• 9.11 Perrigo Company
• 9.12 Pfizer
• 9.13 Philip Morris International
• 9.14 Rusan Pharma
• 9.15 Zydus Group